Background: Diabetes mellitus management is one of the most challenging health care issues in Taiwan. To improve guideline adherence and the quality of diabetes care, the diabetes mellitus pay-for-performance (DM-P4P) program was introduced in 2001. This study examined the effects of the DM-P4P program on guideline adherence among patients with diabetes. Methods: This cross-sectional study used National Health Insurance (NHI) claim data to assess guideline adherence among three groups of patients with diabetes: patients enrolled in the DM-P4P program, patients not enrolled but treated by DM-P4P-participating physicians, and patients treated by non-P4P physicians. Guideline adherence measures included hemoglobin A1c, blood glucose, lipid, serum creatinine, alanine transaminase, urinalysis, and eye examinations. Multiple logistic regression with generalized estimated equation approach were used to assess the effect of the DM-P4P program while controlling for patient and physician characteristics. Results: A total of 520,804 patients were included in the analysis. Patients enrolled in the DM-P4P program were more likely to receive all of the guideline-recommended tests/examinations than patients treated by non-P4P physicians. Patients who were not enrolled in the program but who were treated by DM-P4P-participating physicians were more likely to receive three of the seven recommended tests/examinations than were those treated by non-P4P physicians. Conclusion: When physicians participated in the P4P program, this increased the likelihood that patients would receive guideline-recommended tests or examinations. Increasing the DM-P4P participation rates for physicians and patients are important and worthwhile objectives that can assist in the effort to more effectively manage diabetes in the general population.
Introduction
Clinical guidelines are recommended by healthcare professionals to increase the effectiveness both of patient diagnosis and treatment. 1 Pay-for-performance (P4P) programs, which provide financial rewards for healthcare providers to increase adherence to care guidelines, have become a major policy priority in many countries. 2e4 Despite the increased use of P4P designated programs, the results of previous studies evaluating the effect of P4P on guideline adherence have been inconclusive. Some studies 5e8 found that patients treated by P4P-participating physicians were more likely to receive quality care than patients who were not treated by P4P physicians, whereas other studies 9,10 found a modest effect or no effect. It would appear that more research is needed to verify the effectiveness of P4P programs.
Diabetes mellitus (DM) management is one of the most challenging healthcare issues in Taiwan. There are 1.51 million patients with diabetes, 11 and the prevalence of diabetes in people age 19 years and older is 9.05%. 12 In addition, diabetes has been ranked as the fifth leading cause of death since 1987. Previous studies have reported that diabetes management and quality of care are less than optimal. This may be due in part to poor provider adherence to practice guidelines and significant variation among physician specialties, which are commonplace in Taiwan. 15e17 In 2001, the Bureau of National Health Insurance (NHI) introduced a P4P program for DM, which aimed to improve guideline adherence and quality of diabetes care among clinical practitioners.
Physicians who have completed continuing medical education (CME) and receive a "Diabetes Shared Care Program" (DSCP) certificate from the local health authority are eligible to participate in the DM-P4P program. The program offers financial incentives to P4P-participating physicians to enroll their patients with Type 1 or Type 2 diabetes in the DM-P4P program. An additional administration fee, DM education fee, and comprehensive follow-up consultation fee are included in the P4P program for physicians' compensation. Guideline-recommended tests and examinations are process indicators used to monitor the comprehensiveness of follow-up visits. Later, outcome-based indicators, such as hemoglobin A1c and low-density lipoprotein levels, are included as barometers to measure improvement in the incentive program.
Participation in the DM-P4P program is voluntary for physicians; in addition, the physician has the ability to select patients to be enrolled in the P4P program. Evidence shows that patients enrolled in the P4P program have an increased likelihood of receiving guideline-recommended tests and examinations compared with patients who are not enrolled, 18e21 but patients with more severe conditions associated with DM are more likely to be excluded from enrollment. 20, 22 Because the program is a physician-level incentive strategy to improve care quality, profiling and comparing the quality of care provided by different physician groups is a valuable strategy for quality improvement. 23 However, there are few studies exploring the association between guideline adherence and participation in the DM-P4P program at the physician level.
The primary goal of this study is to examine the effect of the DM-P4P program on guideline adherence among patients with diabetes according to physician participation status. We hypothesize that patients enrolled in the DM-P4P program will receive the most comprehensive laboratory tests and physical examinations as recommended by the guidelines; patients who are not enrolled but are treated by P4P-participating physicians will receive less comprehensive tests/examinations, and those treated by nonparticipating physicians (i.e., cannot be enrolled in the program) will receive the least comprehensive tests/examinations.
Methods
The data for this study came from an NHI claim dataset that was obtained from the National Health Research Institute. The dataset included the registry for medical personnel, boardcertified specialists, contracted medical facilities, and ambulatory and inpatient care records. We used a cross-sectional comparison design to investigate the effect of the DM-P4P program on patients in various physician groups. Patients with diabetes were defined as having received a primary diagnosis of diabetes (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 250) on two outpatient visits. Because a patient might visit more than one doctor for diabetes care, the physician she/he visited most frequently for diabetes care was assigned as the "principal provider" for that patient. 24 Physicians who had treated at least 50 patients with DM in 2008 were included. Physicians who were generalists, or who did not specialize in internal medicine, endocrinology, family medicine, or pediatrics were excluded, which enabled the study to represent the primary care providers of diabetes care.
Therefore, two groups of physicians were identified: the P4P-participating physicians who participated in the DM-P4P program in 2008 (n ¼ 908), and those who did not participate in the P4P program (n ¼ 1770). We further divided the patients treated by P4P-participating physicians into two groups: the enrollee group, consisting of patients who had been enrolled in the program in 2008 (n ¼ 146,467), and the potential enrollee group, consisting of patients who were not enrolled in the program (n ¼ 197,145). Because the DSCP certifies physicians for 3 years, physicians could be in or out of the program at any time during the study period. The comparison group consisted of physicians who had not joined the DM-P4P program between 2006 and 2008 (n ¼ 1627) and their patients (n ¼ 177,192). This study is exempt from human subjects review because it used existing, publicly available data collected and compiled by Taiwan's government agencies, and does not include information that could directly or indirectly identify the subjects of this investigation.
Adherence to the guideline measures was the main response variable in this study. The guideline measures suggested by the DM-P4P program included the following seven items: hemoglobin A1c measurement (HbA1c), fasting and postprandial glucose checkup (glucose), lipid profile (lipid), serum creatinine (sCr), alanine transaminase (ALT), urine routine or urine microalbumin (urinalysis), and eyeground examination or ophthalmic photograph (eye). Lipid measurements included serum total cholesterol, fasting serum triglycerides, high-density lipoprotein cholesterol, and lowdensity lipoprotein cholesterol. For each patient, we recorded any claim for any of the measures derived from ambulatory and inpatient care records in 2008. A patient who had tests/examinations of the item more than once was considered to have adherence to this measure.
The independent variables used were dichotomous indicators for whether patients were in the enrollee or potential enrollee groups, using those who were treated by nonparticipating physicians as the comparison group. The covariates included physician sex, age, specialty, practice setting (academic medical center, regional hospital, community hospital, or clinic), number of diabetes patients, institution ownership, and urbanization of institution and patient sex, age, DM treatment (diet-controlled, oral medication only, or treatment with insulin), diabetes complication severity index (DCSI score), 25 and the number of diabetes-related physician visits. The DCSI contains seven categories of complications, which depend on the presence and severity of the complication, and assigns a score to each category (ranging from 0 to 2). This score was calculated annually for each patient based on all primary and secondary diagnostic codes for all of the patients' ambulatory and inpatient visits in that year; higher scores indicate higher levels of severity. The number of diabetes visits represents the frequency of diabetes-related (ICD-9-CM codes 250) ambulatory appointments for each patient in 2008.
Descriptive statistics were calculated for all of the variables for participant and comparison groups and are presented as a percentage or the mean AE standard deviation (SD). The c 2 test and t test were used to examine the between-group differences in categorical and continuous variables, respectively. For each guideline measure, multiple logistic regression models were constructed to calculate estimated odds ratios and 95% confidence intervals comparing the enrollee versus comparison groups and the potential enrollee versus comparison groups. Logistic regression models were fit using the generalized estimating equation (GEE) approach to account for the likely nonindependence among patients treated by the same physician and within the same hospital or clinic. Odds ratios were estimated from GEE logistic regression models, and adjusted for patient and physician characteristics. We further converted the odds ratios to risk ratios because odds ratios may not be the optimal metric when rates are high. 26, 27 SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for the data and statistical analyses.
Results
Physician characteristics according to DM-P4P participation status are shown in Table 1 . Approximately 36% of the physicians participated in the DM-P4P program. Physicians in the P4P physician group were more likely to be female, younger, and included a greater percentage of specialists in endocrinology, whereas comparison group physicians were more likely to practice in clinics, private hospitals, and rural areas. Physicians who participated in the P4P program had a higher average number of patients with diabetes than nonparticipants (378 versus 109), and 53% had more than 180 patients with DM.
A total of 520,804 patients were analyzed (Table 2) , including 146,467 in the enrollee group (who were treated by P4P physicians), 197,145 in the potential enrollee group (who were not enrolled but treated by P4P physicians), and 177,192 in the comparison group (who were treated by nonparticipating physicians). Patients in the enrollee group were more likely to be female, older, and have a higher number of diabetes-related visits, whereas those in the potential enrollee group were more likely to be treated with insulin and have a higher DCSI score. Patients in the comparison group were more likely to be older, treated with oral medication, have a lower DCSI score, and have fewer diabetes-related visits than those in the enrollee or potential enrollee groups.
For all seven tests and examinations, patients in the enrollee group were more likely to receive these tests/examinations than those in the comparison group; these figures were also higher in the potential enrollee group than in the comparison group (Table 3) . Statistically significant differences were observed between the enrollee group and the comparison group for HbA1c (100% vs. 85%) glucose testing (100% vs. 96%), lipid profile (80% vs. 28%), sCr (93% vs. 74%), ALT (91% vs. 65%), urinalysis (77% vs. 24%), and eye examination (67% vs. 19%). Similarly, statistically significant differences were observed between the potential enrollee group and comparison group, with the potential enrollee group having a higher adherence rate to HbA1c (92% vs. 85%), glucose testing (98% vs. 96%), lipid profile (41% vs. 28%), sCr (85% vs. 74%), ALT (79% vs. 65%), urinalysis (38% vs.9%), and eye examination (27% vs. 19%).
The results of the regression models, controlled for both patient and physician characteristics, are shown in Table 4 . Patients in the enrollee group were significantly more likely to receive each of the seven guideline-recommended measures compared with patients in the comparison group. Patients in the potential enrollee group were significantly more likely to receive three of the seven recommended tests/examinations (lipid, ALT, and eye examination) than patients in the comparison group.
Discussion
This study compared the degree of guideline adherence between DM-P4P-participating physicians and non-P4P physicians by examining the recommended tests or examinations received by their patients. The results supported our hypotheses that DM-P4P enrollees would receive the most comprehensive guideline-recommended tests/examinations, that patients who were not enrolled but were treated by P4P-participating physicians would receive less comprehensive tests/examinations, and that patients treated by nonparticipating physicians would receive the least comprehensive tests/ examinations. Our findings suggest that the DM-P4P program, through CME and reimbursement incentives to the participating physicians, significantly increased the provision of guideline-recommended tests or examinations to their patients. These results are similar to those of certain previous studies.
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Not surprisingly, patients enrolled in the DM-P4P program are more likely to receive all of the guideline-recommended laboratory tests and examinations than are nonenrollees; similar results have been reported by other groups. Moreover, these findings also show that patients who were not enrolled in the P4P program but were treated by DM-P4P-participating physicians were more likely to receive three of the seven tests/examinations than those treated by non-P4P physicians. Because these patients were not enrolled in the P4P program, there was no financial incentive for the physician to provide comprehensive care, including recommended tests and examinations.
The better performance of DM-P4P-participating physicians in providing guideline-recommended care might be due to increased awareness through CME or the physician's established practice pattern. CME is an effective way to enhance professional practice 28 ; therefore, the participating physicians might be aware of current guidelines, and thus are more likely to follow the guideline recommendations. However, some studies have indicated that physicians who already followed clinical guidelines or were more receptive to the P4P program were more likely to participate in the program. 5, 6, 10 Regardless of the explanations for the physicians' differential performance, it is clear that patients treated by nonparticipating physicians receive the least comprehensive care. Increasing the DM-P4P participation rate of the physicians or encouraging patients with DM to be treated by P4P-participating physicians could prove to be valuable policy options for health authorities. Further studies may investigate and analyze the factors associated with physician participation in the program, or possibly the attitudes and concerns of nonparticipating physicians, both intended to provide more specific and sophisticated strategies for improving participation.
The results also highlighted several potential risks of patient selection and treatment disparity in the patients treated by DM-P4P-participating physicians. Less than half (43%) of the patients treated by DM-P4P-participating physicians had been enrolled in the P4P program. Patients with more severe complications (e.g., higher DCSI score) or insulin dependency were more likely to be excluded from joining the program. This finding is consistent with previous studies of the DM-P4P program. 20, 22 It is possible that patients with more comorbidities or insulin prescriptions require greater applied efforts to achieve treatment targets, 29, 30 which is important in a system where the physicians have full discretion to enroll patients into the program. In addition, the inability to reconcile patient preferences with guideline recommendations is a barrier to physician adherence to guidelines. 31 Because the DM-P4P program requires that all program enrollees receive a comprehensive education program, hard-to-manage patients are more likely to be excluded.
However, the problem of patient selection may also indicate a possible deficiency of the reimbursement program, which may require remediation. Several approaches have been proposed to address this challenge, including mandated participation, risk-adjustment of quality indicators, setting maximum achievement thresholds below 100%, and excluding specific patients from the index calculations. 22, 32 In addition, further analysis of the factors associated with low provision rates of specific tests/examinations, such as lipid tests, urinalysis, and eye examination, for nonenrolled patients might provide more information about noncompliance.
It should be noted that this study has several limitations. The study excluded physicians with fewer than 50 patients with DM, which is the mandated threshold of financial reward for the achievement of patient outcomes. Consequently, the results are not representative of low-volume physicians. The lack of information on patient socioeconomic status and education might bias our findings; previous reports have revealed that these variables are associated with patient adherence to medical advice. 33, 34 In conclusion, physicians participating in the DM-P4P program provided significantly more guideline-recommended tests and examinations to their patients. Furthermore, patients who were treated by nonparticipating physicians received less comprehensive care than patients treated by P4P-participating physicians. Due to the high prevalence of diabetes in Taiwan, any and all efforts to increase DM-P4P participation rates for physicians and patients are both worthwhile and necessary.
